13 active not recruiting, 9 completed, 5 recruiting, 3 withdrawn. 18 Phase 2, 14 Phase 1, 1 Early Phase 1.
Follow Recurrent Medulloblastoma: new trials by email Literature Review of Recurrent Medulloblastoma trials Research Report on Recurrent Medulloblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS) 25 mCi 177Lu- DTPA-omburtamab - Recurrent Medulloblastoma, Refractory Medulloblastoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 24 | 2026-07-02 | 2026-10-08 |
| RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs) - Recurrent Medulloblastoma | Phase 1 | Active not recruiting | University of Florida | 24 | 2026-04-24 | 2026-09-29 |
| GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults GPC2-CAR T cells, Fludarabine, Cyclophosphamide - Medulloblastoma, Central Nervous System Embryonal Tumor | Phase 1 | Recruiting | Stanford University | 18 | 2025-08-28 | 2026-10-09 |
| Parental Distress and Treatment Adherence in Pediatric Recurrent Medulloblastoma Not applicable- observational study - Medulloblastoma, Recurrent Medulloblastoma | Withdrawn | West China Hospital | 2025-06-01 | 2026-08-19 | ||
| PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma PEP-CMV, Temozolomide, Tetanus Diphtheria Vaccine - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Phase 2 | Recruiting | Nationwide Children's Hospital | 120 | 2024-07-18 | 2026-08-24 |
| Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies Nivolumab, Methotrexate, 5-Azacytidine - Recurrent Ependymoma, Recurrent Medulloblastoma | Phase 1 | Withdrawn | Jeffrey Treiber | 2024-07-15 | 2026-01-08 | |
| Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors LUTATHERA® (Lutetium Lu 177 dotatate) - High Grade Glioma, Meningioma | Phase 1 / Phase 2 | Recruiting | Nationwide Children's Hospital | 65 | 2022-11-21 | 2026-07-20 |
| 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma Irinotecan, Temozolomide, Bevacizumab - Recurrent Medulloblastoma, Recurrent Ependymoma | Phase 2 | Active not recruiting | Pediatric Brain Tumor Consortium | 62 | 2022-04-04 | 2026-07-28 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer Etoposide, Fludarabine Phosphate, Hematopoietic Cell Transplantation - Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2021-01-14 | 2024-10-26 | |
| Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children Apatinib Combined With Temozolomide and Etoposide Capsules - Recurrent Medulloblastoma | Phase 2 | Recruiting | Beijing Sanbo Brain Hospital | 44 | 2020-10-28 | 2024-10-15 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-10-16 |
| Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Ivosidenib - Recurrent Ependymoma, Recurrent Ewing Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 3 | 2020-07-20 | 2026-07-01 |
| Fimepinostat in Treating Brain Tumors in Children and Young Adults Fimepinostat, Therapeutic Conventional Surgery - Diffuse Intrinsic Pontine Glioma, Recurrent Anaplastic Astrocytoma | Early Phase 1 | Active not recruiting | Sabine Mueller, MD, PhD | 30 | 2019-08-07 | 2026-10-05 |
| Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors Biospecimen Collection, Magnetic Resonance Imaging, Savolitinib - Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 41 | 2018-11-27 | 2026-07-30 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-11-14 | 2026-09-21 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma PEP-CMV - Recurrent Medulloblastoma, Recurrent Brain Tumor, Childhood | Phase 1 | Active not recruiting | Daniel Landi | 30 | 2018-06-29 | 2026-06-18 |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2018-04-17 | 2026-10-06 |
| SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Gemcitabine, ribociclib, sonidegib - Anaplastic Astrocytoma, Anaplastic Ependymoma | Phase 1 | Completed | St. Jude Children's Research Hospital | 68 | 2018-03-05 | 2024-05-31 |
Showing 20 of 31. Sign in to see all of them.
Medulloblastoma (31) · Glioma (20) · Ependymoma (18) · Rhabdoid Tumor (15) · Central Nervous System Neoplasms (12) · Neuroblastoma (12) · Neuroectodermal Tumors, Primitive, Peripheral (12) · Rhabdomyosarcoma (12) · Hepatoblastoma (11) · Histiocytosis, Langerhans-Cell (11) · Lymphoma, Non-Hodgkin (11) · Osteosarcoma (11) · Sarcoma (11) · Wilms Tumor (11) · Sarcoma, Ewing (8)
Neoplasms by Histologic Type (31) · Neoplasms, Glandular and Epithelial (31) · Neoplasms, Nerve Tissue (31) · Neuroectodermal Tumors (31) · Neoplasms (30) · Neoplasms, Neuroepithelial (30) · Neoplasms, Germ Cell and Embryonal (28) · Neuroectodermal Tumors, Primitive (25) · Neoplasms by Site (24) · Nervous System Diseases (19) · Nervous System Neoplasms (19) · Neoplasms, Complex and Mixed (15) · Brain Diseases (12) · Central Nervous System Diseases (12) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (12)
Magnetic Resonance Spectroscopy (7) · Phantoms, Imaging (6) · Specimen Handling (6) · X-Rays (6) · Nuclear Medicine Department, Hospital (4) · Temozolomide (4) · Biopsy (3) · Irinotecan (3) · Bevacizumab (2) · Etoposide (2) · LY3023414 (2) · Melphalan (2) · ensartinib (2) · ivosidenib (2) · larotrectinib (2)
National Cancer Institute (NCI) (15) · M.D. Anderson Cancer Center (2) · Nationwide Children's Hospital (2) · Pediatric Brain Tumor Consortium (2) · Beijing Sanbo Brain Hospital (1) · Daniel Landi (1) · Jeffrey Treiber (1) · Memorial Sloan Kettering Cancer Center (1) · OHSU Knight Cancer Institute (1) · Sabine Mueller, MD, PhD (1) · St. Jude Children's Research Hospital (1) · Stanford University (1) · University of Florida (1) · West China Hospital (1)
United States (27) · Puerto Rico (12) · Canada (6) · Australia (5) · China (2) · New Zealand (1) · Switzerland (1)
Daniel Landi, MD (2) · Sabine Mueller, MD, PhD (2) · Adam S Levy (1) · Andrea T Franson (1) · Christine A Pratilas (1) · Donald W Parsons (1) · Edward A Neuwelt (1) · Elias Sayour, MD, PhD (1) · Elizabeth D Alva (1) · Eric M Thompson, MD (1) · Eugene I Hwang (1) · Giles W. Robinson, MD (1) · Jeffrey M. Treiber, MD (1) · Julia Glade-Bender (1) · Katherine A Janeway (1)
PMID 31401903, PMID 33591402, PMID 34486544, PMID 35353553, PMID 38815151, PMID 38935895, PMID 39298716, PMID 41166674, PMID 42686334, PMID 42853672, PMID 42867148
U10CA180886 (12), UM1CA081457 (4), P30CA016672 (1), R01NS044687 (1), U10CA098543 (1), UM1CA097452 (1)